What question did this study set out to answer?

To assess the real-world treatment patterns and effectiveness of elranatamab in patients with multiple myeloma.

April 25, 2026Future Oncology

Real-world treatment patterns and outcomes of patients with multiple myeloma initiating elranatamab: results from the ALTITUDE-1 and ALTITUDE-2 retrospective cohort studies

View Full Paper

Ask AI

Bookmark

Authors

RBRahul BanerjeeCape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa MMMeera MohanMedical College of Wisconsin BSBhavesh ShahBoston Medical Center

Discussion

Member takes

Implication

Retrospective cohort studies evaluate effectiveness of elranatamab in heavily pre-treated multiple myeloma patients, suggesting real-world consistency with trials.

Key Points

To assess the real-world treatment patterns and effectiveness of elranatamab in patients with multiple myeloma.
Analyzed data from ALTITUDE-1 and ALTITUDE-2 retrospective cohort studies.
Examined treatment patterns and outcomes of US patients initiating elranatamab.
Compared real-world findings with results from MagnetisMM-3 trial (NCT04649359).
Patients were heavily pre-treated before starting elranatamab.
Less frequent administration of elranatamab was observed compared to labeled indications.
Effectiveness aligned with findings from the MagnetisMM-3 clinical trial.

Cite This Study

Banerjee et al. (2026) studied this question.

synapsesocial.com/papers/69ec5aa788ba6daa22dac34f https://doi.org/10.1080/14796694.2026.2662504

View Full Paper

Ask AI

Bookmark

Implication

Retrospective cohort studies evaluate effectiveness of elranatamab in heavily pre-treated multiple myeloma patients, suggesting real-world consistency with trials.

Real-world treatment patterns and outcomes of patients with multiple myeloma initiating elranatamab: results from the ALTITUDE-1 and ALTITUDE-2 retrospective cohort studies

Discussion

Member takes

Implication

Key Points

Cite This Study

Real-world treatment patterns and outcomes of patients with multiple myeloma initiating elranatamab: results from the ALTITUDE-1 and ALTITUDE-2 retrospective cohort studies

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider